Status:
COMPLETED
Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the effects of multiple doses of verapamil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Body mass index in the range of 18 to 30 kg/m2 and body weight greater than 50 kg.
- Healthy as determined by the investigator on the basis of medical history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12-lead ECG readings.
- Exclusion criteria :
- Presence or history of any disorder that may prevent the successful completion of the study.
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal (GI), endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00745576
Start Date
October 1 2008
End Date
December 1 2008
Last Update
February 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gières, France, 38610